Trial Profile

A Phase I clinical study to evaluate lipid nanoparticle (LNP)/mRNA formulations of influenza vaccine

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 13 Jul 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs MRNA-based flu vaccine-Sanofi Pasteur/Translate Bio (Primary)
Indications Influenza virus infections
Focus Adverse reactions

Most Recent Events

05 Aug 2021 According to a Translate Bio media release, interim results from this trial are expected by the end of 2021.
22 Jun 2021 According to a Sanofi Pasteur media release, the company have initiated this study.
22 Jun 2021 Status changed from planning to recruiting, according to a Sanofi Pasteur media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com